RESUMO
On the basis of structural data gathered during our ongoing HIV-1 protease inhibitors program, from which our clinical candidate TMC114 9 was selected, we have discovered new series of fused heteroaromatic sulfonamides. The further extension into the P2' region was aimed at identifying new classes of compounds with an improved broad spectrum activity and acceptable pharmacokinetic properties. Several of these compounds display an exceptional broad spectrum activity against a panel of highly cross-resistant mutants. Certain members of these series exhibit favorable pharmacokinetic profiles in rat and dog. Crystal structures and molecular modeling were used to rationalize the broad spectrum profile resulting from the extension into the P2' pocket of the HIV-1 protease.
Assuntos
Benzoxazóis/síntese química , Farmacorresistência Viral Múltipla , Inibidores da Protease de HIV/síntese química , HIV-1/efeitos dos fármacos , Sulfonamidas/síntese química , Tiazóis/síntese química , Animais , Benzoxazóis/química , Benzoxazóis/farmacologia , Sítios de Ligação , Calorimetria , Linhagem Celular , Cristalografia por Raios X , Cães , Estabilidade de Medicamentos , Inibidores da Protease de HIV/química , Inibidores da Protease de HIV/farmacologia , Humanos , Técnicas In Vitro , Microssomos Hepáticos/metabolismo , Modelos Moleculares , Ratos , Ratos Wistar , Sulfonamidas/química , Sulfonamidas/farmacologia , Termodinâmica , Tiazóis/química , Tiazóis/farmacologiaRESUMO
The screening of known HIV-1 protease inhibitors against a panel of multi-drug-resistant viruses revealed the potent activity of TMC126 on drug-resistant mutants. In comparison to amprenavir, the improved affinity of TMC126 is largely the result of one extra hydrogen bond to the backbone of the protein in the P2 pocket. Modification of the substitution pattern on the phenylsulfonamide P2' substituent of TMC126 created an interesting SAR, with the close analogue TMC114 being found to have a similar antiviral activity against the mutant and the wild-type viruses. X-ray and thermodynamic studies on both wild-type and mutant enzymes showed an extremely high enthalpy driven affinity of TMC114 for HIV-1 protease. In vitro selection of mutants resistant to TMC114 starting from wild-type virus proved to be extremely difficult; this was not the case for other close analogues. Therefore, the extra H-bond to the backbone in the P2 pocket cannot be the only explanation for the interesting antiviral profile of TMC114. Absorption studies in animals indicated that TMC114 has pharmacokinetic properties comparable to currently approved HIV-1 protease inhibitors.